Anticoagulant Dysfunction of Human Arg352Trp-Activated Protein C Caused by Defective Factor Va Inactivation

Claudia Rintelen; Subramanian Yegneswaran; John H. Griffin

doi:10.1055/s-0037-1615694

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2001; 85(02): 274-279
DOI: 10.1055/s-0037-1615694

Review Article

Schattauer GmbH

Anticoagulant Dysfunction of Human Arg352Trp-Activated Protein C Caused by Defective Factor Va Inactivation

Claudia Rintelen^*

¹Departments of Molecular & Experimental Medicine and of Vascular Biology, The Scripps Research Institute, La Jolla, CA, USA

,

Subramanian Yegneswaran

¹Departments of Molecular & Experimental Medicine and of Vascular Biology, The Scripps Research Institute, La Jolla, CA, USA

,

John H. Griffin

¹Departments of Molecular & Experimental Medicine and of Vascular Biology, The Scripps Research Institute, La Jolla, CA, USA

› Author Affiliations

Abstract

Summary

The dysfunctional mutant R352W-protein C was found in two patients with venous thrombosis. The mutant R352A-protein C was constructed to define the contribution of charge/size of the residue at 352 on protein C (chymotrypsin numbering 187). Compared with wild type-protein C, R352W-protein C showed no difference in activation by thrombin·thrombomodulin or α-thrombin. However, R352W-activated protein C (APC) anticoagulant activity (aPTT assay) was reduced to ~65%. Although the catalytic efficiency of R352W-APC towards the oligopeptide substrate S-2366 was unperturbed, factor Va and R506Q-factor Va were not efficiently inactivated by R352W-APC compared with wild type-APC. R352A-APC showed reduced anticoagulant activity and reduced efficiency in factor Va inactivation and in factor VIIIa-inactivation in the presence of protein S. These observations suggest that the dysfunction of R352W-APC in factor Va inactivation may be one of the mechanisms leading to venous thrombosis in affected patients and that R352 plays an important role in the physiological functioning of APC.

Keywords

Venous thrombosis - protein C deficiency - point mutation - factor Va - dysfunction - anticoagulant

Full Text

References

References
1 Esmon CT. The regulation of natural anticoagulant pathways. Science 1987; 235: 1348-52.
2 Dahlbäck B, Stenflo J. The protein C anticoagulant system. In: The Molecular Basis of Blood Diseases 2^nd Edition. Stamatoyannopoulos G, Nienhuis AW, Majerus PW, Varmus H. eds. Chapter 17 W: B. Saunders; 1994. p 599-627.
3 Griffin JH. Regulation of Coagulation. In: William’s Hematology. 6th Edition. Beutler E, Coller B, Kipps T, Lichtman M, Seligsohn U. eds. Chapter 115 2000. in press.
4 Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and factor Va by activated protein C. J Biol Chem 1994; 269: 31869-80.
5 Heeb MJ, Kojima Y, Greengard JS, Griffin JH. Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V. Blood 1995; 85: 3405-11.
6 Eaton D, Rodriquez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986; 25: 505-12.
7 Fay PJ, Smudzin TM, Walker FJ. Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity. J Biol Chem 1991; 266: 20139-45.
8 Rosing J, Hoekema L, Nicolaes GAF, Thomassen MCLGD, Hemker HC, Varadi K, Schwarz HP, Tans G. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270: 27852-8.
9 Yegneswaran S, Wood GM, Esmon CT, Johnson AE. Protein S alters the active site location of activated protein C above the membrane surface. A fluorescence resonance energy transfer study of topography. J Biol Chem 1997; 272: 25013-21.
10 Yegneswaran S, Smirnov MD, Safa O, Esmon NL, Esmon CT, Johnson AE. Relocating the active site of activated protein C eliminates the need for its protein S cofactor. A fluorescence resonance energy transfer study. J Biol Chem 1999; 274: 5462-8.
11 Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-3.
12 Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Arterioscler Thromb Vasc Biol 1996; 16: 742-8.
13 Greengard JS, Fisher CL, Villoutreix B, Griffin JH. Structural basis for type I and type II deficiencies of antithrombotic plasma protein C: patterns revealed by three-dimensional molecular modeling of mutations of the pro-tease domain. Proteins 1994; 18: 367-80.
14 Branson HE, Katz J, Marble R, Griffin JH. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet 1983; 2: 1165-8.
15 Seligsohn U, Berger A, Abend M, Rubin L, Attias D, Zivelin A, Rapaport SI. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med 1984; 310: 559-62.
16 Reitsma PH, Bernardi F, Doig RG, Gandrille S, Greengard JS, Ireland H, Krawczak M, Lind B, Long GL, Poort SR. Protein C deficiency: a database of mutations, 1995 update. On behalf of the subcommittee on plasma coagulation inhibitors of the scientific and standardization committee of the ISTH. Thromb Haemost 1995; 73: 876-89.
17 Faioni EM, Hermida J, Rovida E, Razzari C, Asti D, Zeinali S, Mannucci PM. Type II protein C deficiency: identification of molecular modelling of two natural mutants with low anticoagulant and normal amidolytic activity. Br J Haematol 2000; 108: 265-71.
18 Mather T, Oganessyan V, Hof P, Huber R, Foundling S, Esmon C, Bode W. The 2.8 Å crystal structure of Gla-domainless activated protein C. EMBO J 1996; 15: 6822-31.
19 Fisher CL, Greengard JS, Griffin JH. Models of the serine protease domain of the human antithrombotic plasma factor activated protein C and its zymogen. Protein Sci 1994; 3: 588-99.
20 Gruber A, Griffin JH, Harker L, Hanson SR. Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model. Blood 1989; 73: 639-42.
21 Heeb MJ, Mesters RM, Tans G, Rosing J, Griffin JH. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem 1993; 268: 2872-7.
22 Mesters RM, Houghten RA, Griffin JH. Identification of a sequence of human activated protein C (residues 390-404) essential for its anticoagulant activity. J Biol Chem 1991; 266: 24514-9.
23 Gale AJ, Sun X, Heeb MJ, Griffin JH. Nonenzymatic anticoagulant activity of the serine protease Ser360Ala-activated protein C mediated by factor Va. Protein Sci 1997; 6: 132-40.
24 Esmon CT, Esmon NL, Le Bonniec BF, Johnson AE. Methods Enzymol. Protein C activation 1993; 222: 359-85.
25 Chase T, Shaw E. p-Nitrophenyl-p’-guanidinobenzoate HCl: a new active site titrant for trypsin. Biochem Biophys Res Commun 1967; 29: 508-14.
26 Walker FJ, Chavin SI, Fay PJ. Inactivation of factor VIII by activated protein c and protein S. Arch Biochem Biophys 1987; 252: 322-8.
27 Mesters RM, Heeb MJ, Griffin JH. Interactions and inhibition of blood coagulation factor Va involving residues 311-325 of activated protein C. Protein Sci 1993; 2: 1482-9.
28 Mesters RM, Heeb MJ, Griffin JH. A novel exosite in the light chain of human activated protein C essential for interaction with blood coagulation factor Va. Biochemistry 1993; 32: 12656-63.
29 Fay PJ. Regulation of factor VIIIa in the intrinsic factor Xase. Thromb Haemost 1999; 82: 193-200.
30 O’Brien LM, Mastri M, Fay PJ. Regulation of factor VIIIa by human activated protein C and protein S: inactivation of cofactor in the intrinsic factor Xase. Blood 2000; 95: 1714-20.